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Purpose: Cancer increases the risk of venous thromboembolism (VTE) substantially. VTE
is connected with poorer outcome in cancer patients. The aim of our study was to inves-
tigate the impact of cancer on the severity and short-term outcome of pulmonary embo-
lism (PE). Methods: We retrospectively analyzed the data of 182 patients with confirmed
PE. PE patients were subdivided in the group with concomitant active cancer disease or
history of cancer or in the group without cancer. Groups were compared with Wilco-
xon–Mann–Whitney Test. Logistic regression models were calculated to investigate the
association between cancer and several parameters such as age and PE severity status
as well as the association between in-hospital death and the parameters age, gender, PE
severity status and cancer. Results: While 20.3% PE patients reported an active cancer
disease or a history of cancer (64.9% female), 79.7% of the PE patients did not (60.7%
female). PE patients with cancer were 5 years older (76.0 (65.5/81.0) vs. 71.0 (58.5/80.5)
years, P = 0.055) and revealed a higher PE severity status in mean (1.91  0.53 vs. 1.67
 0.54, P = 0.069). Univariate logistic regression models showed an association between
cancer and age (OR 1.04, CI 95% (1.01–1.08), P = 0.017) as well as cancer and the severity
status (OR 2.38 (1.05–5.26), P = 0.037). In-hospital death in the early course was strongly
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Introduction
2. Positive venous ultrasound of an extremity consistent
with DVT in patients with typical symptoms of PE (chest
connected with the PE severity status (OR 36.60 (2.99–448.68), P = 0.0049), but not with
cancer (P = 0.65). Conclusions: Concomitant history of cancer in acute PE was associated
with higher PE severity status and therefore poorer outcome.
© 2015 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved.
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(VTE = pulmonary embolism (PE) + deep vein thrombosis
(DVT)) substantially [1, 2]. Patients with cancer reveal a 4- to
7-fold higher risk to develop a venous thromboembolic
event in comparison to those patients without cancer [2–6].
The association between cancer and VTE is well known for
a long time. As long ago as in the 19th century Armand
Trousseau first described an association between cancer and
venous thrombotic events [2, 6, 7].
Besides the higher risk to develop a VTE, VTE in patients
with cancer is connected with poorer outcome and shorter
survival [2, 3, 8–15]. VTE is – besides the cancer itself – the
second leading cause of death in patients with cancer [2].
However, most of the studies do not differentiate between
PE and DVT, but investigate VTE in general.
The aim of our study was to investigate the impact of
cancer on the severity status of PE and on in-hospital death
of the PE patients.
Methods
Study design
We performed a retrospective analysis of all patients with
a confirmed diagnosis of acute PE, who were treated at the
internal medicine department between May 2006 and June
2011. Medical records of 182 consecutive PE patients were
reviewed for medical history (symptoms and history), exam-
inations (transthoracic 2D-echocardiography, CT, V/Q-scan,
Doppler ultrasound of the leg veins) and laboratory para-
meters.
In studies with retrospective analysis of diagnostic stan-
dard data no ethic statement is needed in Germany.
Enrolled subjects
Patients were eligible for our study if they were at least 18
years old, treated in the internal medicine department of
the hospital and had a confirmed acute PE. The patients
were identified by performing a search on the hospital
information system database for the diagnostic code of PE
(ICD-10-Code I26).
Confirmation of PE was defined if the patient had one of
the following criteria:
1. Computed tomography (CT) pulmonary angiogram of the
chest with an identified filling defect in the pulmonary
artery system.pain or dyspnea) and positive D-dimer.
3. Scintigraphic ventilation–perfusion (V/Q) scan read as
high probability for PE.
All of the radiographic images were analyzed by experi-
enced radiologists. If the diagnosis of PE was not confirmed
by these criteria, then the patients were not included in this
study.
Study groups
In this study, PE patients were subdivided into 2 groups:
1. PE + cancer group with PE patients with concomitant
active cancer disease or a history of cancer. We did not
differentiate types of cancer.
2. PE S cancer group without concomitant cancer or history
of cancer.
Laboratory examinations
We focused for laboratory examinations on the levels of
cardiac Troponin I (cTnI), CK, creatinine and D-dimer.
A myocardial necrosis was defined as an elevation of cTnI
value >0.1 ng/ml. D-dimer measurements were performed
using an enzyme linked immunosorbent assay. D-dimer
elevation was defined as a D-dimer value of >0.110 mg/l.
Severity status of PE
The PE severity status was defined according to the
European Society of Cardiology (ESC) guidelines and AHA
scientific statement [16, 17]. PE patients with a systolic blood
pressure of <90 mmHg were classified as high-risk PE
patients (massive PE = PE status 3 in statistical calculation)
[16, 17]. Normotensive PE patients were included in the non-
high-risk PE patient group [17]. Further classification of
hemodynamic stable patients was made according to the
RVD and the biomarker levels (especially cTnI) [17].
RVD was defined according to the AHA scientific statement
[16] as a right ventricular (RV) septal–lateral diameter in
4 chamber view in a CT or echocardiography divided by a left
ventricular (LV) septal–lateral diameter >0.9 [16]. Moreover,
the RVD was defined as RV hypokinesis and tricuspid regur-
gitation in echocardiography [16]. Pulmonary artery pressure
was measured as systolic pulmonary artery pressure (sPAP) in
a 4-chamber view of transthoracic echocardiography.
Normotensive PE patients (non-high-risk PE patients) were
classified as patients with intermediate risk due to existing
RVD or positive biomarker levels as cTnI (submassive PE = PE
status 2 in statistical calculation), and PE patients with low
Fig. 1 – Age of the PE group with and without known cancer.
Box plots with median and per quartiles
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risk PE = PE status 1 in statistical calculation) [16, 17].
Study parameters
The retrospectively analyzed parameters included patients’
baseline characteristics and history, risk factors, clinical
characteristics of the PE event, laboratory findings, ECG data,
echocardiography, radiographic findings and death in the
hospital. The ECG was evaluated for complete or incomplete
right bundle branch block (RBBB) and SI-QIII-type.
Statistics
Clinical characteristics, laboratory findings, radiographic and
echocardiographic data and in-hospital death were com-
pared. The commercially available software BIAS® (version
10.04) was used for the computerized analysis. Statistical
analysis of the 2 groups was performed using the Wilcoxon–
Mann–Whitney Test. For statistical comparison of the PE
severity status of the two groups the PE severity status was
analyzed as PE status 1 to 3, like mentioned above.
Moreover univariate logistic regression models were
calculated for the association between cancer and the
parameters age, gender, PE severity status, lung infarction
with pneumonia, DVT, chest pain, dyspnea, haemoptysis
syncope, surgery or trauma in the last 3 months before PE
event, VTE event in patient's history and RVD as well as
cancer and the parameters cTnI, CK, creatinine, D-dimer,
systolic and diastolic blood pressure, RBBB, SI-QIII-type and
sPAP. Furthermore a logistic regression model for the
association between in-hospital death and the parameters
age, gender, PE severity status and cancer was performed.
P-values of <0.05 were considered as statistically signifi-
cant.
Results
Between May 2006 and June 2011, a total number of 182
patients (61.5% female) with confirmed PE were included in
this study. Mean age of the PE patients was 68.5  15.3 years
(female: 70.8  15.1 years; male: 64.9  15.0 years). PE diag-
nosis was confirmed in 156 patients (85.7%) using CT. In 19
patients V/Q scan (10.4%) leads to the diagnosis and in
7 patients (3.8%) diagnosis was made by positive venous
ultrasound of an extremity, which was consistent with DVT
in patients with typical symptoms of PE (chest pain or
dyspnea) and positive D-dimer value.
Out of the 182 PE patients, 7 patients (3.8%) presented
with hemodynamic instable PE (high-risk PE patients) and
175 PE patients (96.2%) were normotensive and classified as
non-high risk PE patients. Eighty-eight normotensive PE
patients (50.3%) showed RVD in the echocardiography and/
or CT and/or positive cTnI levels (PE with intermediate
risk = submassive PE) and 87 patients (49.7%) were classified
as non-high-risk PE without RVD or cTnI elevation (low risk
PE). Five patients (2.7%) died an in-hospital death.
Thirty-seven (20.3%) PE patients had an active cancer
disease or a history of cancer (64.9% female). In contrast 145(79.7%) of the PE patients did not show a concomitant
known cancer disease or history of cancer (60.7% female).
PE patients with concomitant active cancer disease or
history of cancer were in median 5 years older (76.0 (65.5/
81.0) vs. 71.0 (58.5/80.5) years, P = 0.055) (Fig. 1) and revealed
a higher PE severity status in mean (1.91  0.53 vs. 1.67
 0.54, P = 0.069) with a trend toward significance. Patients’
characteristics were shown in Table I. The frequency of PE
patients with known cancer diseases increases over the age
groups (Fig. 2).
While more than 1/3 of the PE patients without cancer
had a low-risk PE, only less than 1/5 of the PE patients with
concomitant active cancer disease or history of cancer were
classified as low-risk PE. The majority of PE patients of both
groups were in the submassive PE status (PE + cancer 71.9%
vs. PE  cancer 59.5%). The percentage of high-risk-PE was
higher in PE + cancer group than in PE  cancer (9.4% vs.
3.6%) (Tab. I).
Univariate logistic regression models showed an associa-
tion between cancer and age (OR 1.04, CI 95% (1.01–1.08),
P = 0.017) as well as cancer and PE severity status (OR 2.38,
CI 95% (1.05–5.26), P = 0.037) and the symptom of chest pain
(OR 0.34, CI 95% (0.12–0.98), P = 0.045) (Tab. II), but not with
the examined laboratory markers (Tab. III). An in-hospital
death in the early course was strongly connected with the
PE severity status (OR 36.60 (2.99–448.68), P = 0.0049), but not
with known cancer (P = 0.65) (Tab. IV).
Discussion
Cancer and its treatments are well-known risk factors for
both VTE-entities, for PE as well as DVT [3, 6, 8, 10, 11, 18–
21]. In addition, VTE is a well-recognized complication of
malignant diseases [5, 6, 22–24]. The potential life-threaten-
ing VTE entity of PE is significantly more common among
cancer patients than in those without [25, 26]. Moreover
patients with acute VTE have an increased risk of occult
malignancy [6, 7, 27–31]. The VTE risk in each cancer patient
varies, depending on cancer-specific and patient-specific
factors [3, 5, 6, 10]. Cancer-specific factors are tumor type and
Table I – PE patients’ characteristics. P-values of <0.05 were considered as statistically significant
PE + cancer
PE patients with concomitant
active cancer disease




cancer or history of cancer
P-value
Age (Median, quartile) 76.0 (65.5/81.0) years 71.0 (58.5/80.5) years 0.055
Gender (females) 64.9% 60.7% 0.64
PE status (mean  SD) 1.91  0.53
(Low risk PE: 18.8%, submassive
PE: 71.9%, massive PE: 9.4%)
1.67  0.54
(Low risk PE: 36.9%, submassive
PE: 59.5%, massive PE: 3.6%)
0.069
In hospital death 2.7% 2.8% 0.99
Lung infarction with pneumonia 40.1% 46.2% 0.54
DVT 73.0% 64.8% 0.35
Surgery or trauma in the last 3 months
before PE event
13.5% 19.3% 0.42
VTE event in patients’ medical history 18.9% 25.2% 0.43
Symptoms at admission
Chest pain 21.6% 35.9% 0.10
Dyspnea 24.3% 17.2% 0.33
Haemoptysis 2.7% 3.5% 0.82
Syncope/collapse 8.1% 11.7% 0.53
Systolic blood pressure (mean  SD) 139.51  33.30 mmHg 144.68  29.40 mmHg 0.55
Diastolic blood pressure (mean  SD) 75.76  19.81 mmHg 77.86  19.76 mmHg 0.58
ECG parameters
Heart rate per minute (mean  SD) 95.35  17.61 beats/min 93.41  26.51 beats/min 0.22
RBBB 8.8% 14.2% 0.63
SI-QIII-type 8.8% 9.9% 0.92
Transthoracic echocardiography
RVD 70.0% 56.1% 0.27
sPAP (mean  SD) 36.91  21.18 mmHg 33.38  17.61 mmHg 0.54
sPAP > 30 mmHg 68.2% 58.0% 0.46
sPAP > 50 mmHg 13.6% 13.4% 0.99
Laboratory parameters
cTnI (mean  SD) 0.15  0.22 ng/ml 0.12  0.29 ng/ml 0.16
CK (mean  SD) 70.97  66.59 U/l 98.37  188.15 U/l 0.070
Creatinine (mean  SD) 1.07  0.29 mg/dl 1.11  0.38 mg/dl 0.98
D-dimer (mean  SD) 3.12  4.12 mg/l 2.56  3.46 mg/l 0.35
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supportive regimes [1, 3, 6, 10, 32, 33]. Patient-specific factors
comprise history of previous VTE, obesity, co-morbidities,
higher age, genetic predisposition and high leukocyte andFig. 2 – Percentage of PE patients with active cancer disease
or cancer in history in the age groups <60 years, 60–69
years, 70–79 years and 80+ yearsplatelet counts [1, 3, 10, 34]. Besides the higher risk to develop
a VTE event in cancer patients, VTE in patients with cancer is
strongly connected with elevated complication rate, like
recurrent VTE or bleeding events [11, 35–37], poorer outcome
and shorter survival [2, 3, 8–10, 22, 31, 34, 38–40]. Besides the
cancer itself, VTE is the second leading cause of death in
patients with cancer [2, 5, 30]. Especially PE is an important
cause of death in cancer patients [11]. However, most of the
studies do not differentiate between the entities of PE and
DVT, but investigate VTE in general.
The aim of our study was to investigate the impact of
cancer on the PE severity status and short-term outcome of
the PE patients.
The results of our study showed a strong association of
cancer with higher PE severity status. PE patients with
active cancer disease or history of cancer revealed a 2.4-fold
higher risk for advanced PE severity status than those PE
patients without cancer. Accordingly, PE patients with
cancer had higher percentages of submassive as well as
massive PE status than those without cancer.
Our study failed to confirm a significant direct associa-
tion between cancer and in-hospital death, although PE
severity status was strongly associated with in-hospital
Table II – Univariable logistic regression model to analyze
the association between cancer and the parameters age,
gender, PE status, lung infarction with pneumonia, DVT,
chest pain, dyspnea, haemoptysis, syncope/collapse,
surgery or trauma in the last 3 months before PE event,
VTE event in patients’ medical history and RVD. P-values
of <0.05 were considered as statistically significant
OR (95% CI) P-value
Active cancer disease or cancer in patients’ medical history
Age 1.04 (1.01–1.08) 0.017
Gender 1.02 (0.44–2.33) 0.97




DVT 1.96 (0.73–5.26) 0.18
Chest pain 0.34 (0.12–0.98) 0.045
Dyspnea 0.58 (0.20–1.69) 0.33
Haemoptysis 0.91 (0.10–8.33) 0.93
Syncope/collapse 0.90 (0.23–3.45) 0.87
Surgery or trauma in
the last 3 months
before PE event
0.79 (0.26–2.33) 0.67
VTE event in patients’
medical history
0.69 (0.25–1.89) 0.47
RVD 1.59 (0.66–3.84) 0.31
Table IV – Univariate logistic regression model to analyze
the association between in-hospital death and the age,
gender, PE status and cancer. P-values of <0.05 were
considered as statistically significant
OR (95% CI) P-value
In-hospital death
Age 1.11 (0.95–1.29) 0.17
Gender 0.72 (0.06–8.33) 0.79
PE stadium 36.60 (2.99–448.68) 0.0049
Active cancer disease
or cancer in patients’
medical history
1.75 (0.15–0.05–20) 0.65
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associated with PE severity status. Higher PE severity status
revealed a 36.6-fold increased risk of in-hospital death.
Therefore, a higher PE severity status in PE patients with
cancer is not a minor result, but rather an important
outcome result. A higher age in PE patients with cancer is
not surprising. An association between many cancer entities
and aging process is well known [6, 41].
Several studies have shown a poorer outcome of VTE
patients with malignancy in comparison to those without
and therefore are in coherence with the results of our study
[5, 8, 9, 13, 42]. Already in 1980, Shen and Pollak [43] reported
a 1.8-fold higher frequency of fatal PE in cancer patients than
in those patients without cancer [43]. Also Carson et al. [12]
described a 3.8-fold increased 1-year mortality in PE patientsTable III – Univariate logistic regression model to analyze
the association between cancer and the parameters cTnI,
CK, creatinine, D-dimer, systolic blood pressure, diastolic
blood pressure, heart rate, RBBB, SI-QIII-type and sPAP. P-
values of <0.05 were considered as statistically significant
OR (95% CI) P-value
Active cancer disease or cancer in patients’ medical history
cTnI 1.08 (0.17–6.67) 0.93
CK 1.01 (1.00–1.03) 0.11
Creatinine 1.41 (0.38–5.26) 0.61
D-dimer 0.94 (0.85–1.04) 0.23
Systolic blood pressure 1.01 (0.99–1.03) 0.45
Diastolic blood pressure 1.00 (0.97–1.02) 0.91
Heart rate 0.99 (0.97–1.01) 0.59
RBBB 1.45 (0.29–7.14) 0.65
SI-QIII-type 1.16 (0.23–5.88) 0.85
sPAP 0.99 (0.97–1.02) 0.64with presence of cancer in comparison to those without
cancer [12]. In coherence, Levitan et al. [8] found a 3.2-fold
higher risk of death after VTE event and a 3-fold higher risk of
recurrent VTE in cancer patients than in those without in the
first 183 days after VTE event [8]. Also Goldhaber et al. [9]
identified cancer as a significant prognostic factor in PE in the
ICOPER study [9]. PE patients with concomitant cancer disease
revealed a 2.3-fold higher mortality after PE event in the first
3 months compared to PE patients without cancer [9]. Monreal
et al. [11] reported a 1.8-fold higher risk of fatal PE and a 3.3-
fold higher frequency of fatal bleedings in PE patients with
cancer than in those PE patients without cancer in the first
3 months after symptomatic PE event [11]. The study results
of Prandoni et al. [35] revealed higher percentages of recurrent
VTE and bleedings in DVT patients [35]. Moreover cancer
diagnosed in the first year after VTE event was connected
with advanced stage of cancer and poorer prognosis in the
study of Sorensen et al. [44] Therefore, several study results
are in coherence with our study and confirm this link between
cancer and VTE [31].
The pathogenesis of VTE and blood coagulation activa-
tion in cancer patients is multi-factorial and complex [3, 5,
18, 23, 24, 31, 34]. Especially cancer growth process is
associated with hypercoaguable state [23, 24, 45]. Also
cancer patients without thrombosis commonly present
with hypercoagulation seen in the laboratory coagulation
tests [23, 24]. Tumor cells activate the coagulation and
haemostatic system on the one hand; on the other hand
the tumor can compress the venous system, which results
in stasis of blood flow and cancer patients often have to
undergo surgery more frequently, chemotherapy with or
without adjuvant supportive and/or hormone therapy and
radiotherapy with concomitant hospitalization, reduced
mobility and central venous catheters [5, 24, 31, 46–48]. The
activation of the haemostatic system by tumor cells
involves several haemostatic pathways [1, 3, 5, 23, 24, 31,
45]. A major role play tumor cell-specific clot promoting
properties [3, 31]. Key factors are tumor factor expression,
elevation of haemostatic markers, inflammatory cytokines,
acute phase reactants, tissue factor as well as cancer
proagulant and paraprotein production, adhesions of
tumor cells with platelets, endothelial cells as well as
leucocytes, necrosis (factors) and elevated production of
microparticels and cytokines by tumor cells or host cells [1,
3, 24, 31, 45, 48]. Activation of the coagulation cascade and
haemostatic cellular components are leading to thrombin
a c t a h a e m a t o l o g i c a p o l o n i c a 4 6 ( 2 0 1 5 ) 3 7 8 – 3 8 4 383generation and fibrin formation [3, 24, 31]. Moreover
proteins and cellular components of haemostasis and
coagulation seem to play an important role in tumor
neoangionesis and metastasis formation at the same time
[3, 23, 24, 30, 31, 45]. The tumor-associated prothrombotic
state contributes to the process of tumor dissemination and
growth. Therefore, tumor growth and metastasis formation
are connected with higher frequency of VTE events [23, 24,
30, 33, 34, 46].
Conclusions
Concomitant history of cancer in acute PE was associated
with higher PE severity status and therefore poorer out-
come.
Limitations and strength
Our study has several limitations. Data quality is reduced
due to the study design (single center, retrospective data
analysis). The single-center study design study in a larger
general hospital of basic and regular medical care could
lead to a selection bias. Severe PE cases and younger PE
patients could be taken to specialist units of university
medical center (chest pain unit), which is located in the
nearer surrounding in the same city. We did not assess
further co-morbidities than the presented ones. This will be
the subject of further examinations. Moreover we did not
assess the cancer types and stages and therapeutic differ-
ences of the enrolled patients. This is a major limitation of
this study.
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